|
1
|
Reardon DA, Rich JN, Friedman HS and
Bigner DD: Recent advances in the treatment of malignant
astrocytoma. J Clin Oncol. 24:1253–1265. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Holland EC: Gliomagenesis: Genetic
alterations and mouse models. Nat Rev Genet. 2:120–129. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clarke J, Butowski N and Chang S: Recent
advances in therapy for glioblastoma. Arch Neurol. 67:279–283.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Babu R, Kranz PG, Agarwal V, McLendon RE,
Thomas S, Friedman AH, Bigner DD and Adamson C: Malignant brainstem
gliomas in adults: Clinicopathological characteristics and
prognostic factors. J Neurooncol. 119:177–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grauer OM, Wesseling P and Adema GJ:
Immunotherapy of diffuse gliomas: Biological background, current
status and future developments. Brain Pathol. 19:674–693. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Almeida MI, Reis RM and Calin GA: MicroRNA
history: Discovery, recent applications, and next frontiers. Mutat
Res. 717:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: MiRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar :
|
|
12
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wen SY, Lin Y, YU YQ, Cao SJ, Zhang R,
Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a
tumor suppressor by directly targeting the hedgehog pathway
transcription factor Gli3 in human cervical cancer. Oncogene.
34:717–725. 2015. View Article : Google Scholar
|
|
15
|
Yu F, Lv M, Li D, Cai H, Ma L, Luo Q, Yuan
X and Lv Z: miR-506 overexpression inhibits proliferation and
metastasis of breast cancer cells. Med Sci Monit. 21:1687–1692.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y,
Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K,
et al: miR-506 inhibits multiple targets in the
epithelial-to-mesenchymal transition network and is associated with
good prognosis in epithelial ovarian cancer. J Pathol. 235:25–36.
2015. View Article : Google Scholar
|
|
17
|
Deng L and Liu H: MicroRNA-506 suppresses
growth and metastasis of oral squamous cell carcinoma via targeting
GATA6. Int J Clin Exp Med. 8:1862–1870. 2015.PubMed/NCBI
|
|
18
|
Sakimura S, Sugimachi K, Kurashige J, Ueda
M, Hirata H, Nambara S, Komatsu H, Saito T, Takano Y, Uchi R, et
al: The miR-506-induced epithelial-mesenchymal transition is
involved in poor prognosis for patients with gastric cancer. Ann
Surg Oncol. Feb 24–2015.Epub ahead of print. View Article : Google Scholar
|
|
19
|
Karsy M, Arslan E and Moy F: Current
progress on understanding microRNAs in glioblastoma multiforme.
Genes Cancer. 3:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tivnan A and McDonald KL: Current progress
for the use of miRNAs in glioblastoma treatment. Mol Neurobiol.
48:757–768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang
D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, et al:
miR-506 suppresses proliferation and induces senescence by directly
targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol.
233:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y, Liu H, Li Y, Wu J, Greenlee AR,
Yang C and Jiang Y: The role of miR-506 in transformed 16HBE cells
induced by anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide.
Toxicol Lett. 205:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang FQ, Zhang HM, Chen SJ, Yan Y and
Zheng JH: miR-506 is downregulated in clear cell renal cell
carcinoma and inhibits cell growth and metastasis via targeting
FLOT1. PLoS One. 10:e01202582015. View Article : Google Scholar
|
|
24
|
Sun Y, Mezzanzanica D and Zhang W:
miR-506: A multitasker in suppression of the
epithelial-to-mesenchymal transition. RNA Dis.
1:e4472014.PubMed/NCBI
|
|
25
|
Arora H, Qureshi R and Park WY: miR-506
regulates epithelial mesenchymal transition in breast cancer cell
lines. PLoS One. 8:e642732013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM,
Xiao SD and Ran ZH: MicroRNA 506 regulates expression of PPAR alpha
in hydroxycamptothecin-resistant human colon cancer cells. FEBS
Lett. 585:3560–3568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Streicher KL, Zhu W, Lehmann KP,
Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice
DA, Higgs BW, et al: A novel oncogenic role for the miRNA-506-514
cluster in initiating melanocyte transformation and promoting
melanoma growth. Oncogene. 31:1558–1570. 2012. View Article : Google Scholar
|
|
28
|
Siciliano V, Garzilli I, Fracassi C,
Criscuolo S, Ventre S and di Bernardo D: MiRNAs confer phenotypic
robustness to gene networks by suppressing biological noise. Nat
Commun. 4:23642013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alvarez JV, Mukherjee N, Chakravarti A,
Robe P, Zhai G, Chakladar A, Loeffler J, Black P and Frank DA: A
STAT3 gene expression signature in gliomas is associated with a
poor prognosis. Transl Oncogenomics. 2:99–105. 2007.PubMed/NCBI
|
|
30
|
Turkson J: STAT proteins as novel targets
for cancer drug discovery. Expert Opin Ther Targets. 8:409–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Masuda M, Suzui M, Yasumatu R, Nakashima
T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
|
32
|
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao
AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, et al: STAT3
activation regulates the expression of vascular endothelial growth
factor and human pancreatic cancer angiogenesis and metastasis.
Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: STAT3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alas S and Bonavida B: Rituximab
inactivates signal transducer and activation of transcription 3
(STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of
the interleukin 10 autocrine/paracrine loop and results in
down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
Cancer Res. 61:5137–5144. 2001.PubMed/NCBI
|
|
35
|
Aoki Y, Feldman GM and Tosato G:
Inhibition of STAT3 signaling induces apoptosis and decreases
survivin expression in primary effusion lymphoma. Blood.
101:1535–1542. 2003. View Article : Google Scholar
|
